登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验。牵头方不是本站收录的医院;本站收录的 12 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 12
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心首都医科大学附属北京同仁医院Beijing Tongren Hospital北京医院页面
- 研究中心重庆大学附属肿瘤医院Chongqing University Cancer Hospital重庆医院页面
- 研究中心温州医科大学附属第一医院First Affiliated Hospital of Wenzhou Medical University温州医院页面
- 研究中心郑州大学第一附属医院First Affiliated Hospital of Zhengzhou University郑州医院页面
- 研究中心中国医科大学附属第一医院First Hospital of China Medical University沈阳医院页面
- 研究中心吉林大学第一医院First Hospital of Jilin University长春医院页面
- 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面
- 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
- 研究中心广西医科大学附属肿瘤医院Guangxi Medical University Cancer Hospital南宁医院页面
- 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
- 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
- 研究中心四川大学华西医院West China Hospital成都医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06084936,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically-confirmed MCL, with documentation of either overexpression of cyclin D1 or the presence of t(11:14) within 12 months of study entry
入选标准第 2 条
At least 1 line of prior systemic therapy including a BTK inhibitor and additional systemic therapy option
入选标准第 4 条
Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3
排除标准第 5 条
Treatment with systemic therapy or BTK inhibitors, or any investigational agent for the purposes of treating cancer within 2 weeks or 5 half-lives (whichever is shorter) prior to first study treatment
排除标准第 7 条
Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at study enrollment or any major episode of infection within 4 weeks prior to the first study treatment
排除标准第 12 条
Adverse events from prior anti-cancer therapy that have not resolved to Grade 1 or better
排除标准第 18 条
Prior treatment with systemic immunosuppressive medications within 2 weeks or five half-lives (whichever is shorter) prior to the first dose of study treatment
排除标准第 23 条
Corticosteroid therapy within 2 weeks prior to first dose of study treatment
排除标准第 24 条
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
入选标准第 7 条
At least one bi-dimensionally measurable (defined as at least 1.5 cm) nodal lesion, or one bi-dimensionally measurable (at least 1 cm) extranodal lesion, as measured on CT scan
入选标准第 6 条
Positive test for hepatitis B virus (HBV) or hepatitis C virus (HCV)
排除标准第 14 条
Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 3 months after the final dose of tocilizumab, 2 months after the final dose of glofitamab, whichever is longer
排除标准第 1 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06084936,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Life expectancy at least 12 weeks Histologically-confirmed MCL, with documentation of either overexpression of cyclin D1 or the presence of t(11:14) within 12 months of study entry Relapsed (disease progression after the last treatment regimen) or refractory (failure to achieve a partial or complete response from the last treatment regimen) disease At least 1 line of prior systemic therapy including a BTK inhibitor and additional systemic therapy option Confirmed availability of tumor tissue, unless deemed unsafe per investigator assessment At least one bi-dimensionally measurable (defined as at least 1.5 cm) nodal lesion, or one bi-dimensionally measurable (at least 1 cm) extranodal lesion, as measured on CT scan Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 Negative HIV test at screening Adequate hematological function排除标准:Exclusion Criteria:
Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 3 months after the final dose of tocilizumab, 2 months after the final dose of glofitamab, whichever is longer Leukemic, non-nodal MCL History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products Contraindication to obinutuzumab or rituximab, and either bendamustine or lenalidomide Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3 Prior treatment with CAR-T cell therapy Treatment with systemic therapy or BTK inhibitors, or any investigational agent for the purposes of treating cancer within 2 weeks or 5 half-lives (whichever is shorter) prior to first study treatment Primary or secondary CNS lymphoma at the time of recruitment or history of CNS lymphoma Current or history of CNS disease, such as stroke, epilepisy, CNS vasculitis, or neurodegenerative disease History of other malignancy that could affect compliance with the protocol or interpretation of results Significant or extensive cardiovascular disease Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at study enrollment or any major episode of infection within 4 weeks prior to the first study treatment Suspected or latent tuberculosis Positive test for hepatitis B virus (HBV) or hepatitis C virus (HCV) Known or suspected chronic active Epstein-Barr viral infection (EBV) Known or suspected history of hemophagocytic lymphohistiocytosis (HLH) Known history of progressive multifocal leukoencephalopathy (PML) Adverse events from prior anti-cancer therapy that have not resolved to Grade 1 or better Administration of a live, attenuated vaccine within 4 weeks before first study treatment administration or anticipation that such a live, attenuated vaccine will be required during the study Prior solid organ transplantation or allogenic stem cell transplant Eligibility for stem cell transplantation (SCT) Active autoimmune disease requiring treatment Prior treatment with systemic immunosuppressive medications within 2 weeks or five half-lives (whichever is shorter) prior to the first dose of study treatment Corticosteroid therapy within 2 weeks prior to first dose of study treatment Recent major surgery (within 4 weeks before the first study treatment) other than for diagnosis Clinically significant history of cirrhotic liver disease
引自 ClinicalTrials.gov, NCT06084936, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06084936,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。